SCHEDULE 13D/A: RA Capital Management Increases Stake in Werewolf Therapeutics to 15.0%

RA Capital Management, L.P. and its affiliates have increased their beneficial ownership in Werewolf Therapeutics, Inc. to 15.0% through recent open market purchases.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Reporting Persons") have filed Amendment No. 6 to their Schedule 13D regarding their beneficial ownership of Werewolf Therapeutics, Inc. common stock.
• The Reporting Persons collectively beneficially own 6,746,807 shares of Werewolf Therapeutics, Inc. common stock, representing 15.0% of the outstanding shares.
• This ownership includes 6,237,482 shares held directly by RA Capital Healthcare Fund, L.P., 443,825 shares by RA Capital Nexus Fund II, L.P., and 65,500 shares underlying stock options for Dr. Derek DiRocco (48,000 vested, 17,500 vesting within 60 days).
• RA Capital Healthcare Fund, L.P. made recent open market purchases: 320,913 shares on May 12, 2025 (weighted-average price $0.86), 52,974 shares on May 13, 2025 (weighted-average price $0.98), and 162,539 shares on May 14, 2025 (weighted-average price $0.98).
• The total shares purchased by the Fund across these three days amount to 536,426 shares.
• The percentage of class is based on 44,873,646 shares outstanding as of May 2, 2025, as reported in the Issuer's Form 10-Q.

Sentiment

Score: 8

Explanation: The document reflects a strong positive sentiment due to a major institutional investor significantly increasing its stake in the company through open market purchases, indicating high confidence in its future prospects.

Positives

• A significant institutional investor, RA Capital Management, has increased its stake, indicating continued confidence in Werewolf Therapeutics.
• The recent purchases were made in the open market, suggesting a belief in the current valuation or future potential of the stock.
• The aggregate beneficial ownership of 15.0% represents a substantial and influential position in the company.

Future Outlook

The document indicates that 17,500 shares underlying stock options for Dr. Derek DiRocco are expected to vest in full on May 24, 2025, with an exercise price of $4.88.

Industry Context

The increased stake by RA Capital Management, a prominent healthcare-focused investment firm, suggests a positive long-term view on Werewolf Therapeutics, Inc., a biotechnology company. Such an investment by a specialized fund can signal confidence in the company's pipeline, strategic direction, or potential for future growth within the competitive biotechnology sector.

Comparison to Industry Standards

• While this filing does not provide financial results for direct comparison, RA Capital Management's increased stake in Werewolf Therapeutics, Inc. is notable. Investment firms like RA Capital often specialize in specific sectors, and their significant positions (15.0% in this case) are typically based on deep due diligence into a company's fundamentals, intellectual property, and market potential, similar to how other major biotech investors like Orbimed or Perceptive Advisors build concentrated positions in promising early to mid-stage biopharmaceutical companies.
• The decision to increase holdings through open market purchases, rather than through a private placement, indicates a belief in the current public market valuation, a common strategy for activist or long-term strategic investors who see value at prevailing prices.

Stakeholder Impact

• Shareholders: The increased stake by a prominent institutional investor may be viewed positively, potentially boosting investor confidence and signaling a belief in the company's long-term value, which could positively influence share price.
• Company Management: The significant ownership by RA Capital Management could lead to increased engagement or influence from the investor on strategic decisions, given their substantial stake.

Next Steps

• The vesting of 17,500 stock options for Dr. Derek DiRocco on May 24, 2025, will result in additional shares being exercisable.

Key Dates

Recommendation

Keywords

Werewolf Therapeutics, RA Capital Management, Schedule 13D/A, Beneficial Ownership, Institutional Investment, Biotechnology, Healthcare Fund, Stock Purchase, Equity Stake